Nov 06, 2013 3:51pm EST Neovasc, an OPKO Supported Company, Reports That Reducer™ Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Function in Patients with Refractory Angina
Nov 04, 2013 8:51am EST OPKO Commences Pivotal Clinical Validation Study for 4Kscore™ as a Predictor of Prostate Cancer Prior to Biopsy
Oct 10, 2013 9:00am EDT OPKO Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies